Identification of potential drug targets for delirium from genetic insights: A Mendelian randomization study

Read full text Summarise with VIRAT
Authors: Yan-Na Geng, Xu Dong, Yuan Liu, Yan Dong
Cited by: 0
References: 62

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Delirium, a prevalent acute cerebral disorder, currently lacks effective pharmacological interventions despite its substantial clinical impact. Leveraging genetic insights represents a valuable approach for advancing therapeutic discovery. This study used Mendelian randomization (MR) to systematically screen druggable genes and prioritize genetic targets for delirium. Among 5883 druggable genes examined, we identified 11 genes with causal evidence supporting their role in delirium susceptibility, of which 5 were further supported by summary-data-based MR (SMR) and HEIDI tests. PSORS1C3 demonstrated significant genetic colocalization with delirium risk (PP.H4 = 0.746), strongly implicating its potential causal role. We also conducted an exploratory two-step MR mediation analysis and found that the genetically proxied expression of POU5F1 and PSORS1C3 may reduce delirium risk potentially by regulating white matter structural connectivity between the left hemisphere salience/ventral attention network and the default mode network. However, these mediation findings are preliminary and require validation in independent cohorts with non-overlapping samples. In conclusion, this study prioritizes PSORS1C3 and POU5F1 as high-confidence candidate genes for delirium susceptibility, providing a genetic foundation for future functional studies and guiding subsequent drug repurposing investigations.

Fields of Study & Subjects

Intensive Care Unit Cognitive Disorders Genetic Associations and Epidemiology Multiple Sclerosis Research Studies

Publication details

Journal / source
Brain Research Bulletin
Volume
238
Pages
111849–111849
Publication date
28 March 2026
Language
EN